Search

Purpose: Tracking severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and positivity trends is crucial for understanding the trajectory of the pandemic. We describe demographic and clinical characteristics, testing, and positivity rates for SARS-CoV-2 among 2.8 million patients evaluated at an urgent care provider., Methods: We conducted a retrospective study of patients receiving a diagnostic or serologic test for SARS-CoV-2 between March 1, 2020 and July 20, 2021 at 115 CityMD locations in the New York metropolitan area. Temporal trends in SARS-CoV-2 positivity by diagnostic and serologic tests stratified by age, sex, race/ethnicity, and borough of residence were assessed., Results: During the study period, 6.1 million COVID diagnostic and serological tests were performed on 2.8 million individuals. Testing levels were higher among 20-29-year-old, non-Hispanic White, and female patients compared with other groups. About 35% were repeat testers. Reverse transcriptase polymerase chain reaction positivity was higher in non-Hispanic Black (7.9%), Hispanic (8.2%), and Native American (8.2%) compared to non-Hispanic White (5.7%) patients. Overall seropositivity was estimated to be 22.1% (95% confidence interval: 22.0-22.2) and was highest among 10-14 year olds (27.9%), and non-Hispanic Black (26.0%) and Hispanic (31.0%) testers., Conclusion: Urgent care centers can provide broad access to diagnostic testing and critical evaluation for ambulatory patients during pandemics, especially in population-dense, urban epicenters.  Urgent care center electronic medical records data can provide in-depth surveillance during pandemics complementary to citywide health department data sources., (Copyright © 2022 Elsevier Inc. All rights reserved.)

The duration of antibody persistence following natural infection is unclear. We examined routine SARS-CoV-2 diagnostic and serological testing data on 6522 persons diagnosed between March 2020 and March 2021 who had at least 1 antibody test ≥30 days after diagnosis at CityMD, an urgent care provider. Using survival analysis, we estimated the median duration of detectable anti-SARS-CoV-2 antibodies and hazard of seroreversion by demographic and clinical characteristics. We found that over 90% (95% CI: 91.8%, 94.8%) of the study population had detectable levels of antibodies at 180 days post diagnosis and that SARS-CoV-2 antibodies persisted at a detectable level for a median duration of 342 days following infection (95% CI: 328, 361). Additionally, there were differences in antibody persistence by age, with older patients less likely to serorevert compared to younger patients. These findings suggest that protection from natural infection may wane with time and differ by demographic factors., (Copyright © 2022 Elsevier Inc. All rights reserved.)